PellePharm, Inc. operates in the biotechnology industry. The company was incorporated in 2012 and is based in Menlo Park, California. Focused on the development of topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas (BCCs) in persons with Gorlin Syndrome and those with sporadic BCCs.